Persons D L, Hartmann L C, Herath J F, Borell T J, Cliby W A, Keeney G L, Jenkins R B
Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota.
Am J Pathol. 1993 Mar;142(3):733-41.
Karyotype information on ovarian carcinomas has been limited because the tumors are often difficult to culture and the resultant metaphases can have complex numerical and structural chromosomal anomalies. Fluorescent in situ hybridization is a rapid method of determining centromere copy number in metaphase cells and interphase nuclei. Fluorescent in situ hybridization was used to determine the numerical centromere complement of chromosomes X, 8, 12, and 17 and HER-2/neu gene amplification within interphase nuclei of 25 primary epithelial ovarian carcinomas. Touch preparations of the carcinomas were hybridized with two-color combinations of directly labeled alpha-satellite centromeric chromosome enumeration probes and a directly labeled HER-2/neu probe. Modal centromere copy numbers for each of the four chromosomes were used to determine numerical abnormalities relative to the flow cytometric DNA ploidy level for each tumor. Four cases were found to be normal with respect to the four chromosomes studied. In the remaining 21 cases a relative loss of chromosomes 17 (16 cases) and X (nine cases) and a relative gain of chromosomes 12 (10 cases) and 8 (nine cases) were the most common findings. In addition, the HER-2/neu gene was amplified in two of the 25 tumors. In conclusion, fluorescent in situ hybridization is an excellent method for rapid determination of numerical abnormalities and gene amplification in ovarian carcinomas.
关于卵巢癌的核型信息一直有限,因为这些肿瘤通常难以培养,并且所得到的中期细胞可能具有复杂的染色体数目和结构异常。荧光原位杂交是一种在中期细胞和间期核中确定着丝粒拷贝数的快速方法。荧光原位杂交被用于确定25例原发性上皮性卵巢癌间期核内染色体X、8、12和染色体17的着丝粒数目以及HER-2/neu基因扩增情况。将癌组织的触片与直接标记的α-卫星着丝粒染色体计数探针和直接标记的HER-2/neu探针的双色组合进行杂交。使用这四条染色体各自的着丝粒拷贝数众数来确定相对于每个肿瘤的流式细胞术DNA倍体水平的数目异常情况。在所研究的四条染色体方面,发现有4例正常。在其余21例中,最常见的发现是染色体17(16例)和X(9例)相对缺失,以及染色体12(10例)和8(9例)相对增加。此外,25例肿瘤中有2例HER-2/neu基因发生扩增。总之,荧光原位杂交是快速确定卵巢癌数目异常和基因扩增的一种出色方法。